SLC6A3 and major depressive disorder: For example, behavioral pharmacology studies of DA in MDD suggest that patients experience a much stronger euphoria response to amphetamine than controls [154,155], possibly indicating an up-regulation of post-synaptic DA receptors sites and/or DAT.